03:00 PM EST, 11/12/2025 (MT Newswires) -- Eli Lilly ( LLY ) will discontinue CVS Health's ( CVS ) drug benefit plans for its employees after the pharmacy chain's benefits unit, Caremark, stopped covering its Zepbound weight-loss drug in favor of Novo Nordisk's ( NVO ) Wegovy, Bloomberg reported late Tuesday, citing sources.

Lilly workers will automatically be enrolled with pharmacy benefit coverage through Rightway, starting Jan. 1, 2026, according to a document cited by Bloomberg.

CVS offers plans with both Lilly's Zepbound and Novo's Wegovy, but that option is more expensive for plan sponsors compared with its standard offering, which excludes Zepbound, according to the report.

Eli Lilly ( LLY ) did not immediately respond to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 1009.06, Change: +20.44, Percent Change: +2.07